A molecular diagnostic and therapeutic platform for targeting PI3Kδ-S isoform to combat endocrine cancers
This technology identifies a cancer-promoting protein variant, PI3Kδ-S, as a biomarker and drug target, and shows that combining a splicing inhibitor with a PI3Kδ inhibitor can better treat aggressive, drug-resistant endocrine and solid tumors.
Background
The Phosphoinositide 3-kinase (PI3K)/AKT signaling pathway is a fundamental regulator of cell growth, proliferation, and survival, and its dysregulation is a hallmark of many human cancers. When aberrantly activated, this pathway promotes uncontrolled cell division, tumor growth, and metastasis. This pervasive involvement makes it a critical area of focus for oncology research, particularly in aggressive forms like endocrine cancers, where effective therapeutic strategies are urgently needed to overcome disease progression and improve patient outcomes.
Despite the critical role of the PI3K/AKT pathway in cancer, current therapeutic approaches targeting this pathway often encounter significant limitations. A major challenge is the emergence of drug resistance, where tumors develop mechanisms to evade the effects of inhibitors. This can be due to the existence of specific oncogenic variants or splice isoforms within the pathway that function independently of normal regulatory mechanisms, such as tumor suppressors. These variants are often unaffected by conventional PI3K inhibitors, allowing cancer cells to continue proliferating and driving disease progression, thereby limiting the efficacy of existing treatments and leading to treatment failure in advanced cancers.
Technology
This technology identifies and utilizes an aberrant splice isoform of PI3Kδ, known as PI3Kδ-S, as both a potential biomarker and a therapeutic target for various cancers, especially endocrine tumors. PI3Kδ-S is a variant resulting from alternative splicing, which exhibits oncogenic properties that promote tumor aggressiveness and drug resistance. It has been found to be highly expressed in aggressive endocrine and solid tumors. The approach involves detecting this specific variant and understanding its role in cancer progression, providing a new avenue for diagnosis and treatment.
A key differentiation lies in PI3Kδ-S’s unique biological behavior. Unlike the full-length PI3Kδ-L, this variant operates independently of the tumor suppressor PTEN, allowing it to drive cancer progression even when PTEN is non-functional. Consequently, standard PI3Kδ inhibitors, such as Idelalisib, are ineffective against PI3Kδ-S. The novel strategy combines a splicing inhibitor, SRPIN340, to reduce PI3Kδ-S levels with existing PI3Kδ inhibitors. This synergistic combination therapy effectively reduces tumor cell viability and growth, offering a promising solution for advanced cancers that are resistant to conventional treatments by targeting a previously unaddressed oncogenic pathway.
Benefits
- Enables identification of PI3Kδ-S as a biomarker for aggressive endocrine and solid tumors
- Targets a splice variant (PI3Kδ-S) that promotes tumor aggressiveness and drug resistance
- Offers a combination therapy approach using splicing inhibitor SRPIN340 and PI3Kδ inhibitor Idelalisib for synergistic tumor suppression
- Addresses drug resistance by targeting PI3Kδ-S, which is independent of tumor suppressor PTEN regulation
- Improves treatment outcomes for advanced endocrine cancers through modulation of aberrant splicing
- Provides a foundation for developing novel therapies including splicing factor targeting and PI3Kδ-S specific inhibitors
Applications
- Endocrine cancer diagnostic biomarker
- Combination therapy for drug-resistant cancers
- Prognostic tool for tumor aggressiveness
- Development of PI3Kδ-S specific inhibitors
Additional info
This work identifies an oncogenic PI3Kδ splice isoform, PI3Kδ-S, promoting tumor aggressiveness and drug resistance in endocrine cancers, independent of PTEN. It serves as a biomarker for cancer aggressiveness. A therapeutic approach combines a splicing inhibitor, SRPIN340, to reduce PI3Kδ-S levels, with a PI3Kδ inhibitor, Idelalisib, demonstrating synergistic efficacy against cancer cell viability and growth.